Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tylenol Gains On COX-2 Fallout, Drives J&J Consumer Sales

This article was originally published in The Tan Sheet

Executive Summary

Tylenol first-quarter sales benefited from the publicity surrounding COX-2 safety issues, according to Johnson & Johnson

You may also be interested in...

Tylenol extensions

Extra Strength Rapid Release Gels "have specially designed holes in the gelcap that allow the medicine to be released more quickly than before," McNeil announces. The gels are rolling out now at food, drug and mass retailers in 24-, 50- and 100-count packages with SRPs of $4.99, $6.00 and $9.99, respectively. Rapid Release will be backed by a national campaign. Tylenol Allergy Complete (acetaminophen, chlorpheniramine maleate and pseudoephedrine HCl) features the brand's Cool Burst coating to provide "an instant cooling sensation upon administration of the medicine." The 24-and 48-count packages will cost $5.99 and $8.99 when they hit shelves in March, supported by radio and an April 3 FSI drop...

J&J Increases European Consumer Stake With Merck Buyout

Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts